The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of ...

Meitheal Pharmaceuticals has gained exclusive US commercial rights for XENLETA for treating CABP in the adult population.

The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of tumorigenesis, the TIME attempts to eliminate abnormal cells through immune ...

When a room of physicians at ASH 2024 was asked whether they had prescribed a gene therapy in a commercial context, only a handful said yes.

Hepion Pharmaceuticals ( (HEPA) ) just unveiled an announcement.

Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.

Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (the “Company” or “Hepion”), a clinical stage biopharmaceutical company that had ...

The patient, diagnosed with a large hepatocellular carcinoma in the right lobe of the liver, faced significant challenges due ...

Hepatocellular carcinoma (HCC) is a significant global health issue, ranking as the sixth most prevalent malignancy and the ...

Raveesh Kunwar Malik, a 36-year-old lawyer from Zirakpur, donates his organs saving six lives after a tragic motorcycle ...

Hepatitis B virus (HBV) infection contributes to hepatocellular carcinoma (HCC) tumorigenesis, drug resistance, and recurrence, although the ...

Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally ...